A PHASE III, RANDOMISED, OPEN-LABEL STUDY OF SAVOLITINIB IN COMBINATION WITH OSIMERTINIB VERSUS PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH EGFR MUTATED MET OVEREXPRESSED AND/OR AMPLIFIED, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON TREATMENT WITH OSIMERTINIB (SAFFRON)

Registry ID

D5087C00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA AB

Start date

2024-05-20

Last update

2022-06-08

Conditions

• LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER

Related clinical trials

• A PHASE 2/3 OPEN LABEL RANDOMIZED STUDY OF TELISOTUZUMAB ADIZUTECAN COMPARED TO STANDARD OF CARE IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER AFTER PROGRESSION ON A THIRD-GENERATION EGFR TKI - ANDROMETA-LUNG-713
• A GLOBAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FIRMONERTINIB COMPARED WITH INVESTIGATOR’S CHOICE OF OSIMERTINIB OR AFATINIB AS FIRST-LINE TREATMENT IN PARTICIPANTS WHO HAVE LOCALLY ADVANCED OR METASTATIC NON-SMALLCELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR P-LOOP AND ALPHA C-HELIX COMPRESSING (PACC) UNCOMMON MUTATIONS (ALPACCA)
• A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON¿SMALL CELL LUNG CANCER
• A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE STUDY OF DATOPOTAMAB DERUXTECAN OR DOCETAXEL IN PREVIOUSLY TREATED TROP2-POSITIVE ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG17)
• A PHASE 1/2 OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF BH-30643 IN ADULT SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC HARBORING EGFR AND/OR HER2 MUTATIONS (SOLARA)
• A PHASE III, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE, INTERNATIONAL STUDY OF DURVALUMAB PLUS DOMVANALIMAB (AB154) IN PARTICIPANTS WITH LOCALLY ADVANCED (STAGE III), UNRESECTABLE NON SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED FOLLOWING DEFINITIVE PLATINUM BASED CONCURRENT CHEMORADIATION THERAPY (PACIFIC 8)

View on source registry